DOJ To Expand Use Of False Claims Act To Manufacturing And AER Violations
This article was originally published in The Tan Sheet
Executive Summary
Drug manufacturers that sell to the government products that do not meet specifications or that fail to report serious adverse events could face False Claims Act allegations and potentially severe penalties in the near future
You may also be interested in...
Regulatory News In Brief
OTC PPIs add blood-thinner advisory
Regulatory News In Brief
OTC PPIs add blood-thinner advisory
Regulatory News In Brief
OTC PPIs add blood-thinner advisory